SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

The financing round was jointly led by new investor Regeneron Ventures and current investor Deerfield Management.

The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues died from the complications of this malignancy in 2006.

Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...

Camurus announces positive results from POSITANO phase 2b study of octreotide SC depot in patients with symptomatic polycystic liver disease: Lund, Sweden Thursday, June 19, 2025, ...

The CW News at 10pm ...